These Analysts Revise Their Forecasts On Biogen After Q1 Results

Biogen Inc BIIB reported better-than-expected earnings for its first quarter on Wednesday.

Biogen reported first-quarter adjusted EPS of $3.67, up 8%, beating the consensus of $3.44. The company reported sales of $2.29 billion, down 7% year over year and missing the consensus of $2.31 billion, according to data from Benzinga Pro.

Multiple sclerosis revenue of $1.1 billion decreased by 4% (down 4% on constant currency). Multiple sclerosis drug Tysabri sales were down to $431.3 million from $472.8 million. Rare disease revenue decreased 4% year over year (down 4% CC) to $423.9 million. Spinraza's revenue fell to $341.3 million from $443.3 million a year ago.

For the fiscal year 2024, Biogen reaffirms adjusted EPS Of $15.00-$16.00 versus consensus of $15.48, up around 5% versus 2023 at the mid-point. The company expects 2024 total revenue to decline by a low- to mid-single-digit percentage, with operating income expected to grow at a low-double-digit percentage.

Biogen shares gained 4.6% to close at $201.99 on Wednesday.

These analysts made changes to their price targets on Biogen following earnings announcement.

  • HC Wainwright & Co. cut the price target on Biogen from $325 to $300. HC Wainwright & Co. analyst Andrew Fein maintained a Buy rating.
  • Wedbush boosted the price target on Biogen from $213 to $215. Wedbush analyst Laura Chico maintained a Neutral rating.
  • Needham analyst Ami Fadia, meanwhile, reiterated Biogen with a Buy and maintained a $294 price target.

Read More: Jefferies Financial, Maplebear And 2 Other Stocks Insiders Are Selling

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsPrice TargetTrading IdeasPT Changes
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!